Cancer drug discovery preclinical research
Web page: Not specified
Funding details: Related items
Junior researcher in Medicinal Chemistry
Projects: de.NBI-SysBio, Kinetics on the move - Workshop 2016, Example use cases, SBEpo - Systems Biology of Erythropoietin, FAIRDOM & LiSyM & de.NBI Data Structuring Training, FAIRDOM, EnzymeML, GMDS Project Group "FAIRe Dateninfrastrukturen für die Biomedizinische Informatik", FAIRDOM Community Workers, MIX-UP, COVID-19 Disease Map, ERNEST Mapping Group Pilot Study, NMTrypI - New Medicines for Trypanosomatidic Infections, Standardization of enzyme-catalyzed reaction measurement, Standardization of enzyme-catalyzed reaction modelling, ModeleXchange initiative, CoVIDD - Coronavirus interactions in drug discovery - optimization and implementation, Mass spectrometry proteomics for biomarker discovery, Thymidylate synthase dimer dissociation
Institutions: Heidelberg Institute for Theoretical Studies (HITS gGmbH)
https://orcid.org/0000-0002-9077-5664
Programme: Cancer drug discovery preclinical research
Public web page: Not specified
Programme: Cancer drug discovery preclinical research
Public web page: Not specified
The Hippo signalling is a metabolic control pathway of cells proliferation and apoptosis, thus represents an emerging topic in tumour suppression regulation and regenerative medicine. This pathway is activated by anti-proliferative signals which come from the extracellular environment received by membranes proteins. In the cytosol compartment, the pathway is regulated by a phosphorylation cascade of four main proteins with Serin-Treonin kinase activity. At the end-point of this cascade the ...
Programme: Cancer drug discovery preclinical research
Public web page: Not specified
Semi-targeted Mass Spectrometry proteomics study to detect 12 selected proteins of two serum samples belonging to the FOLFOX-4 study on heavly-pretreated ovarian cancer patients. The two samples, F10 and F12, are basal samples collected at before the first FOLFOX-4 treatment cycle (T0) and were selected for this study because they show a different proteome profile.
Download
Supplementary material for "Mass spectrometry proteomic and network enrichment analysis to track FOLFOX response in drug resistant ovarian carcinoma"
